These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
520 related articles for article (PubMed ID: 10717776)
1. Effect of low-dose oral contraceptives on androgenic markers and acne. Thorneycroft IH; Stanczyk FZ; Bradshaw KD; Ballagh SA; Nichols M; Weber ME Contraception; 1999 Nov; 60(5):255-62. PubMed ID: 10717776 [TBL] [Abstract][Full Text] [Related]
2. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Mango D; Ricci S; Manna P; Miggiano GA; Serra GB Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881 [TBL] [Abstract][Full Text] [Related]
3. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Moutos D; Smith S; Zacur H Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446 [TBL] [Abstract][Full Text] [Related]
4. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. Lemay A; Dewailly SD; Grenier R; Huard J J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494 [TBL] [Abstract][Full Text] [Related]
5. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Wiegratz I; Jung-Hoffmann C; Kuhl H Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973 [TBL] [Abstract][Full Text] [Related]
6. Changes in androgens during treatment with four low-dose contraceptives. Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882 [TBL] [Abstract][Full Text] [Related]
7. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. Kuhnz W; Staks T; Jütting G Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098 [TBL] [Abstract][Full Text] [Related]
9. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction. Sulak P; Lippman J; Siu C; Massaro J; Godwin A Contraception; 1999 Mar; 59(3):161-6. PubMed ID: 10382078 [TBL] [Abstract][Full Text] [Related]
10. An open study of Triphasil and Diane 50 in the treatment of acne. Wishart JM Australas J Dermatol; 1991; 32(1):51-4. PubMed ID: 1834045 [TBL] [Abstract][Full Text] [Related]
11. Cycle control with oral contraceptives containing 20 micrograms of ethinyl estradiol. A multicenter, randomized comparison of levonorgestrel/ethinyl estradiol (100 micrograms/20 micrograms) and norethindrone/ethinyl estradiol (1000 micrograms/20 micrograms). DelConte A; Loffer F; Grubb GS Contraception; 1999 Mar; 59(3):187-93. PubMed ID: 10382082 [TBL] [Abstract][Full Text] [Related]
12. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone. Wild RA; Demers LM; Applebaum-Bowden D; Lenker R Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706 [TBL] [Abstract][Full Text] [Related]
13. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. Anderson FD Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552 [TBL] [Abstract][Full Text] [Related]
14. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol. Boyd RA; Zegarac EA; Posvar EL; Flack MR Contraception; 2001 Feb; 63(2):71-6. PubMed ID: 11292470 [TBL] [Abstract][Full Text] [Related]
15. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Godsland IF; Crook D; Devenport M; Wynn V Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185 [TBL] [Abstract][Full Text] [Related]
16. Changes in unbound sex steroids and sex hormone binding globulin--binding capacity during oral and vaginal progestogen administration. Granger LR; Roy S; Mishell DR Am J Obstet Gynecol; 1982 Nov; 144(5):578-84. PubMed ID: 6890312 [TBL] [Abstract][Full Text] [Related]
17. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring. Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404 [TBL] [Abstract][Full Text] [Related]
18. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622 [TBL] [Abstract][Full Text] [Related]
19. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study. Masson S; Franssen E; Hilditch JR; Powell MG Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001 [TBL] [Abstract][Full Text] [Related]
20. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. London RS; Chapdelaine A; Upmalis D; Olson W; Smith J Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]